Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782373 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
A Phase 2 study of VEXAS and Vexas Syndrome, sponsored by Swedish Orphan Biovitrum.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT06782373 is a Phase 2 study of VEXAS and Vexas Syndrome that is actively recruiting participants, run by Swedish Orphan Biovitrum. The registered enrollment target is 78 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06782373, a Phase 2 study of VEXAS and Vexas Syndrome, is actively recruiting participants, sponsored by Swedish Orphan Biovitrum.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pacritinib
Study Locations (20)
Other
- Lille University Hospital Center - Lille
- Saint-Antoine Hospital - APHP - Paris
- Tenon Hospital - APHP - Paris
- Hospices Civils de Lyon - Lyon Sud - Pierre-Bénite
- University Hospital Center of Poitiers - Poitiers
- IUCT-Oncopole - Toulouse
Ohio
- Cleveland Clinic - Cleveland - Cleveland
- The James Cancer Hospital and Solove Research Institute - Columbus
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
Maryland
- University of Maryland Medical Center Midtown Campus - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- NYU Langone Health - New York
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2028-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06782373
The ClinicalTrials.gov registry entry for NCT06782373 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Orphan Biovitrum, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with VEXAS appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06782373 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT06782373 about?
NCT06782373 is a clinical study titled "A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)". This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A...
What is the current status of trial NCT06782373?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2025-05-28. Estimated completion is 2028-05-22.
What conditions does trial NCT06782373 study?
This clinical trial studies the following conditions: VEXAS, Vexas Syndrome.
What interventions are being tested in trial NCT06782373?
The interventions under investigation include: Placebo (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT06782373?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782373 being conducted?
This trial has 20 study locations across Arizona, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for VEXAS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.